Has Alaa Elbendary, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,930 in general payments to Alaa Elbendary, MD across 250 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alaa Elbendary, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alaa Elbendary, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alaa Elbendary, MD

Gynecologic Oncology · Overland Park, KSNPI 1255395687

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.4% of the total across 250 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.

$4,930in general payments, 2019–2025

Across 250 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$796
GSK$768
AstraZeneca$605
Clovis Oncology, Inc.$572
Eisai Inc.$475
Genmab U.S., Inc.$453
plus $1K from 20 others

What the payments were for

Food & beverage$4,85298%
Education$782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	34	$796
GSK	35	$768
AstraZeneca	19	$605
Clovis Oncology, Inc.	68	$572
Eisai Inc.	20	$475
Genmab U.S., Inc.	17	$453
AbbVie	14	$297
Myriad Genetic Laboratories, Inc.	8	$200
Tesaro, Inc.	7	$133
Intuitive Surgical	2	$75
Fennec Pharmaceuticals, Inc.	2	$74
Takeda Pharmaceuticals U.S.A., Inc.	1	$55
Amgen	2	$51
Immunogen, Inc.	2	$51
Baxter Healthcare	2	$49
Integra Lifesciences Corporation	2	$43
Kyowa Kirin, Inc.	3	$43
Mylan Institutional Inc.	2	$39
Ascend Therapeutics US, LLC	2	$32
Tactile Systems Technology Inc	2	$30
Novartis	1	$20
Heron Therapeutics, Inc.	1	$17
Sentynl Therapeutics, Inc.	1	$16
Cumberland Pharmaceuticals, Inc.	1	$13
Menarini Silicon Biosystems, Inc.	1	$13
Johnson & Johnson	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$65,091

Medicare patients

119

Services billed

352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	28	$19,270
Megestrol Acetate	41	$1,602
Estradiol	25	$1,038
Letrozole	44	$761
Warfarin Sodium	174	$755
Dexamethasone	37	$555
Tamoxifen Citrate	34	$535
Potassium Chloride	12	$514
Pantoprazole Sodium	12	$438
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	51	$382
Ondansetron Hcl	60	$357
Prochlorperazine Maleate	42	$340
Tamsulosin Hcl	12	$257
Lisinopril	16	$236
Levothyroxine Sodium	19	$220

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Overland Park

Lindsay HasselwanderWestwood$3K
Sara LangeMerriam$3K
Lowell ByersShawnee Mission$2K
Jacqueline MorganWichita$2K
Yasmin AbedinKansas City$1K
Brenda ShoupMerriam$1K
James DelmoreWichita$852
Michelle DudzinskiShawnee Mission$832
Rana AlianiKansas City$194
Thomas ChavezKansas City$119

See the full list for Kansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →